NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis (Q2907213): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: co-financing rate (P837): 78.43 percentage) |
(Added qualifier: readability score (P590521): 0.000011549073841409742) |
||||||||||||||
(3 intermediate revisions by the same user not shown) | |||||||||||||||
Property / beneficiary name (string) | |||||||||||||||
Property / beneficiary name (string): BSIM THERAPEUTICS, S.A. / rank | |||||||||||||||
Property / beneficiary | |||||||||||||||
Property / beneficiary: Q2988326 (Deleted Item) / rank | |||||||||||||||
Property / budget | |||||||||||||||
| |||||||||||||||
Property / budget: 1,136,308.0 Euro / rank | |||||||||||||||
Property / EU contribution | |||||||||||||||
| |||||||||||||||
Property / EU contribution: 891,221.0 Euro / rank | |||||||||||||||
Property / summary: None (English) / qualifier | |||||||||||||||
readability score: 0.000011549073841409742
| |||||||||||||||
Property / priority axis | |||||||||||||||
Property / priority axis: Strengthening research, technological development and innovation (OT1) / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / thematic objective | |||||||||||||||
Property / thematic objective: Research and innovation / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / beneficiary | |||||||||||||||
Property / beneficiary: BSIM THERAPEUTICS, S.A. / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / beneficiary name (string) | |||||||||||||||
BSIM THERAPEUTICS, S.A. | |||||||||||||||
Property / beneficiary name (string): BSIM THERAPEUTICS, S.A. / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / budget | |||||||||||||||
934,289.9 Euro
| |||||||||||||||
Property / budget: 934,289.9 Euro / rank | |||||||||||||||
Preferred rank | |||||||||||||||
Property / EU contribution | |||||||||||||||
722,832.3 Euro
| |||||||||||||||
Property / EU contribution: 722,832.3 Euro / rank | |||||||||||||||
Preferred rank | |||||||||||||||
Property / co-financing rate | |||||||||||||||
77.37 percent
| |||||||||||||||
Property / co-financing rate: 77.37 percent / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / date of last update | |||||||||||||||
14 November 2023
| |||||||||||||||
Property / date of last update: 14 November 2023 / rank | |||||||||||||||
Normal rank |
Latest revision as of 13:21, 20 March 2024
Project Q2907213 in Portugal
Language | Label | Description | Also known as |
---|---|---|---|
English | NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis |
Project Q2907213 in Portugal |
Statements
722,832.3 Euro
0 references
934,289.9 Euro
0 references
77.37 percent
0 references
16 August 2016
0 references
15 February 2020
0 references
BSIM THERAPEUTICS, S.A.
0 references
14 November 2023
0 references
Identifiers
POCI-01-0247-FEDER-003431
0 references